DRI Capital raises $1.45bn for royalty deals
This article was originally published in Scrip
DRI Capital has raised $1.45bn in private equity for a fund called Drug Royalty III, which gives the Canadian firm $3bn in drug royalty buying capacity when its new cash is combined with available debt.
You may also be interested in...
Public Company Edition: US initial public offerings are reawakening from a brief nap as Prometheus and Longboard prepare IPOs for launch. Also, Halozyme sells $700m worth of notes and Karuna’s $250m stock sale leads recent follow-on offerings.
A year after Organon spun out of Merck, the company has delivered on its financial guidance, generated double-digit biosimilars sales growth and executed six deals to grow in women’s health.
ARCH Venture Partners brought in $2.975bn for its latest fund to give additional long-term investors a place at the table as the VC firm creates, builds and supports new early-stage biotechnology start-ups.